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Memory lasts a lifetime, yet the physiological substrate
of memory, synaptic contacts, are composed of pro-
teins that have much shorter lifetimes. A physiological
analog of memory formation, long-term potentiation
(LTP), has a late protein synthesis dependent phase (L-
LTP) that can last for many hours in slices, or even
days in vivo [1,2]. Our previous studies show that
maintenance of L-LTP and memory can be accounted
by persistent regulation of on-site synthesis of plasti-
city-related proteins by a self-sustaining regulation of
translation. It has been shown that a aCaMKII-CPEB1
molecular pair can act as a bistable switch with differ-
ent total amounts of aCaMKII in potentiated and non-
potentiated synapses [3].
The molecular interaction model in our previous
study comprised aCaMKII which could be in an inac-
tive, active and active and phosphorylated forms
together with a translation regulating molecule CPEB1,
which can be in an active or inactive form. The model
included both degradation and new protein synthesis of
aCaMKII. We have showen that this model is bistable
[3]. The bistability was caused by interaction of Ca
2
+-Calmodulin dependent and auto-phosphorylation acti-
vation, spontaneous degradation and synthesis loops of
aCaMKII. This model could successfully account for
m a i n t e n a n c eo fL - L T Po v e ral o n gp e r i o do ft i m ea n d
also proposes an explanation for why application of pro-
tein synthesis and aCaMKII inhibitors at induction and
maintenance phases of L-LTP result in very different
outcomes [3-5]
However, the protein synthesis loop in our previous
model was very simplistic. Here, we suggest a more
detailed model of translation with explicit implementa-
tion of mRNA and poly-ribosome concentration in the
pre-synaptic spine. We assume that activated CBEB1ac-
tivates mRNA which then binds preferentially to poly-
ribosome, as compared to a non-active mRNA, for
aCaMKII synthesis. We show that this system can act
as a bistable switch. We also look at the behavior of this
system at low poly-ribosome and mRNA concentration
levels using stochastic simulations with Gillespie
algorithm.
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